Interestingly, increasing NMD activity, such as by overexpressing UPF1, can alleviate the phenotypes of amyotrophic lateral sclerosis (ALS) in both in vitro and in vivo models. This evidence concerns the gene UPF1 and amyotrophic lateral sclerosis.